Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that dutasteride affected spinal bone formation in curdlan-treated SKG mice, while DHT treatment reduced osteoblast differentiation in vitro, suggesting that DHT inhibition might unexpectedly increase spinal ankylosis progression in ankylosing spondylitis patients.

This trial will compare the effectiveness of spironolactone to doxycycline for treating acne in adult females, potentially offering an alternative to antibiotics and isotretinoin.

This study found that extracts from the rice variety Bue Bang 3 CMU, particularly the husk and bran, demonstrated antioxidant, anti-inflammatory, and anti-androgenic properties, suggesting potential use in treating androgenetic alopecia.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.

In this phase 3 trial analysis, baricitinib improved scalp hair growth in adults with severe alopecia areata, with a faster and higher response in those receiving 4 mg compared to 2 mg, but response varied with severity at baseline and continued through week 52.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This review discusses the potential and varied uses of spironolactone in dermatological conditions such as acne, hidradenitis suppurativa, hirsutism, and female pattern androgenetic alopecia, emphasizing dosage, treatment recommendations, and adverse effects for practical clinical use.

This study reported that BRL 7660 significantly reduced sebum secretion and acne symptoms in human studies with topical administration, but the placebo effect and commercial pressures halted further investigations.

This study observed that new trienone compounds consistently showed higher 5alpha-reductase inhibitory activity compared to corresponding dienones across various biological models.

This article discusses the underutilization of spironolactone in dermatology for conditions like acne, highlighting its potential benefits and good safety profile, but reports no new clinical findings.

This study used a multi-layer in silico framework to evaluate Korean herbal compounds for androgenetic alopecia, identifying Biochanin A, Saponin Re, and Emodin as potential topical candidates with distinct safety and affinity profiles, although these findings remain purely computational without experimental validation.

In this study, germacrone from Curcuma aeruginosa showed anti-androgenic effects by inhibiting 5α-reductase, suggesting its potential as a lead compound for treating androgen-dependent disorders.

This study found that a hair tonic containing 40% broccoli stalks extract was more effective in promoting hair growth in male white rats compared to lower concentrations, while also maintaining stable physical characteristics and safety during testing.

This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.

This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.

This source suggests that spironolactone, a potassium-sparing diuretic, is underutilized in dermatology despite evidence showing its potential benefits for female acne, hidradenitis suppurativa, and female androgenetic alopecia, noting its long-term safety and reduced need for additional testing in young women.

This study reports that baricitinib was more effective than placebo in promoting hair growth in adults with severe alopecia areata after 36 weeks of treatment in clinical trials.

This study conducted an in silico evaluation of Korean herbal compounds against key targets involved in androgenetic alopecia, finding Biochanin A, Saponin Re, and Emodin as promising candidates for topical treatments, but highlighting safety and topical formulation challenges.

This paper describes recent advancements in the synthesis of thiasteroids but reports no new experimental results, noting that introducing heteroatoms in steroidal structures has potential biological effects.

In this study, women with androgenic alopecia showed increased excretion of steroid metabolites and heightened 5α-reductase activity, suggesting these may contribute to the condition's hormonal abnormalities.

In this study, baricitinib showed promising results in improving scalp, eyebrow, and eyelash hair loss in adults with severe and very severe alopecia areata over 52 weeks.

This study found that Scutellaria baicalensis extract and its main component baicalin inhibited androgen activation signaling and promoted proliferation of human dermal papilla cells, suggesting potential use in treating androgen-associated disorders.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

Baricitinib was effective in treating hair loss in adults with alopecia areata according to patient feedback.